D.E. Shaw & Co’s Abiomed Inc ABMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-10,000
Closed -$2.46M 5382
2022
Q3
$2.46M Hold
10,000
﹤0.01% 2810
2022
Q2
$2.48M Sell
10,000
-10,000
-50% -$2.7M ﹤0.01% 2884
2022
Q1
$6.63M Sell
20,000
-15,500
-44% -$4.77M 0.01% 2007
2021
Q4
$12.8M Buy
35,500
+9,200
+35% +$3.11M 0.01% 1444
2021
Q3
$8.56M Buy
26,300
+10,000
+61% +$3.39M 0.01% 1635
2021
Q2
$5.09M Buy
16,300
+10,000
+159% +$3.07M ﹤0.01% 2026
2021
Q1
$2.01M Sell
6,300
-82,800
-93% -$26.5M ﹤0.01% 2580
2020
Q4
$28.9M Sell
89,100
-9,800
-10% -$2.71M 0.03% 764
2020
Q3
$27.4M Buy
98,900
+11,800
+14% +$3.4M 0.03% 678
2020
Q2
$21M Hold
87,100
0.03% 754
2020
Q1
$12.6M Sell
87,100
-15,500
-15% -$2.57M 0.02% 871
2019
Q4
$17.5M Sell
102,600
-24,900
-20% -$4.62M 0.02% 882
2019
Q3
$22.7M Buy
127,500
+48,500
+61% +$10.5M 0.03% 717
2019
Q2
$20.6M Buy
79,000
+56,500
+251% +$15M 0.03% 731
2019
Q1
$6.43M Sell
22,500
-27,900
-55% -$9.27M 0.01% 1385
2018
Q4
$16.4M Buy
50,400
+12,400
+33% +$4.31M 0.02% 796
2018
Q3
$17.1M Sell
38,000
-300
-0.8% -$118K 0.02% 840
2018
Q2
$15.7M Buy
38,300
+10,800
+39% +$3.91M 0.02% 850
2018
Q1
$8M Buy
+27,500
New +$6.97M 0.01% 1129

Other funds holding ABMD

D.E. Shaw & Co's ABMD Position: Q4 2022 in Review

D.E. Shaw & Co sold out of Abiomed Inc (ABMD) in Q4 2022, closing a stake of 3,448 shares — an estimated $847K sold.

D.E. Shaw & Co first reported a position in ABMD in Q2 2013 and held it in 34 quarters. The position peaked at $39.1M in Q3 2016. 8 funds tracked by Wall St. Rank hold ABMD as of Q4 2022.

  • D.E. Shaw & Co reported no remaining Abiomed Inc position as of Q4 2022 after selling out during the quarter.
  • D.E. Shaw & Co sold 3,448 Abiomed Inc shares in Q4 2022, an estimated $847K.
  • D.E. Shaw & Co first reported a position in Abiomed Inc in Q2 2013 and held it in 34 quarters.
  • D.E. Shaw & Co's Abiomed Inc position peaked at $39.1M in Q3 2016.
  • 8 funds tracked by Wall St. Rank held Abiomed Inc as of Q4 2022.

Based on D.E. Shaw & Co's 13F filing for Q4 2022, filed 14 Feb 2023.